News Releases

Month Year

Sep 2, 2015

RegeneRx to Present at Rodman & Renshaw Global Investment Conference

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Aug 12, 2015

New Publication Elaborates on TB4's Effects on Dry Eye Syndrome and Other Potential Ophthalmic Disorders

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a...
Aug 6, 2015

RegeneRx Provides Update on Clinical Trials in U.S., Korea and China

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today provided an...
Jul 22, 2015

RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jul 17, 2015

RegeneRx Korean Licensee Receives Government Approval to Conduct Phase 2b/3 Clinical Trial in Patients with Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, was informed today...
Jul 14, 2015

U.S. PTO Issues Notice of Allowance for Patent using TB4 for Improving Neurological Outcomes After Injury and Neurodegenerative Disease

Intellectual Property Developed at Henry Ford Hospital System and Licensed to RegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jun 2, 2015

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure

Functional Improvement Six Months After Heart Attack Correlated with Higher TB4 Levels

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced a peer-reviewed publication of the results of a recent cardiac stem cell clinical trial that...
May 22, 2015

RegeneRx to Present at 2 Investor Conferences

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, chief...
May 22, 2015

Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology

Statistically Significant Findings Identify Key Efficacy Targets for Phase IIb/III Clinical Trial with RGN-259

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced a peer-reviewed publication of the results of the Company's 72-patient, placebo-controlled Phase II...
May 8, 2015

Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral Neuropathy and Restores Sciatic Nerve Function

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that independent researchers have...

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa